In recent decades, aside from BRAF inhibitors and mitogen-activated protein kinase (MAPK) inhibitors—which have been shown to extend overall survival—no other effective treatments have emerged, and most clinical trials for advanced melanoma have failed [12,13,14,15]. This evidence concerns the gene BRAF and melanoma.